Pneumomediastinum in COVID-19 : a phenotype of severe COVID-19 pneumonitis? The results of the United Kingdom (POETIC) survey
Copyright ©The authors 2022..
BACKGROUND: There is an emerging understanding that coronavirus disease 2019 (COVID-19) is associated with increased incidence of pneumomediastinum. We aimed to determine its incidence among patients hospitalised with COVID-19 in the United Kingdom and describe factors associated with outcome.
METHODS: A structured survey of pneumomediastinum and its incidence was conducted from September 2020 to February 2021. United Kingdom-wide participation was solicited via respiratory research networks. Identified patients had SARS-CoV-2 infection and radiologically proven pneumomediastinum. The primary outcomes were to determine incidence of pneumomediastinum in COVID-19 and to investigate risk factors associated with patient mortality.
RESULTS: 377 cases of pneumomediastinum in COVID-19 were identified from 58 484 inpatients with COVID-19 at 53 hospitals during the study period, giving an incidence of 0.64%. Overall 120-day mortality in COVID-19 pneumomediastinum was 195/377 (51.7%). Pneumomediastinum in COVID-19 was associated with high rates of mechanical ventilation. 172/377 patients (45.6%) were mechanically ventilated at the point of diagnosis. Mechanical ventilation was the most important predictor of mortality in COVID-19 pneumomediastinum at the time of diagnosis and thereafter (p<0.001) along with increasing age (p<0.01) and diabetes mellitus (p=0.08). Switching patients from continuous positive airways pressure support to oxygen or high flow nasal oxygen after the diagnosis of pneumomediastinum was not associated with difference in mortality.
CONCLUSIONS: Pneumomediastinum appears to be a marker of severe COVID-19 pneumonitis. The majority of patients in whom pneumomediastinum was identified had not been mechanically ventilated at the point of diagnosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
The European respiratory journal - (2022) vom: 12. Mai |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 20.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1183/13993003.02522-2021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM336771851 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM336771851 | ||
| 003 | DE-627 | ||
| 005 | 20240220232028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.02522-2021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM336771851 | ||
| 035 | |a (NLM)35144988 | ||
| 035 | |a (PII)2102522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Melhorn, James |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pneumomediastinum in COVID-19 |b a phenotype of severe COVID-19 pneumonitis? The results of the United Kingdom (POETIC) survey |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright ©The authors 2022. | ||
| 520 | |a BACKGROUND: There is an emerging understanding that coronavirus disease 2019 (COVID-19) is associated with increased incidence of pneumomediastinum. We aimed to determine its incidence among patients hospitalised with COVID-19 in the United Kingdom and describe factors associated with outcome | ||
| 520 | |a METHODS: A structured survey of pneumomediastinum and its incidence was conducted from September 2020 to February 2021. United Kingdom-wide participation was solicited via respiratory research networks. Identified patients had SARS-CoV-2 infection and radiologically proven pneumomediastinum. The primary outcomes were to determine incidence of pneumomediastinum in COVID-19 and to investigate risk factors associated with patient mortality | ||
| 520 | |a RESULTS: 377 cases of pneumomediastinum in COVID-19 were identified from 58 484 inpatients with COVID-19 at 53 hospitals during the study period, giving an incidence of 0.64%. Overall 120-day mortality in COVID-19 pneumomediastinum was 195/377 (51.7%). Pneumomediastinum in COVID-19 was associated with high rates of mechanical ventilation. 172/377 patients (45.6%) were mechanically ventilated at the point of diagnosis. Mechanical ventilation was the most important predictor of mortality in COVID-19 pneumomediastinum at the time of diagnosis and thereafter (p<0.001) along with increasing age (p<0.01) and diabetes mellitus (p=0.08). Switching patients from continuous positive airways pressure support to oxygen or high flow nasal oxygen after the diagnosis of pneumomediastinum was not associated with difference in mortality | ||
| 520 | |a CONCLUSIONS: Pneumomediastinum appears to be a marker of severe COVID-19 pneumonitis. The majority of patients in whom pneumomediastinum was identified had not been mechanically ventilated at the point of diagnosis | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Achaiah, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Conway, Francesca M |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Elizabeth M F |e verfasserin |4 aut | |
| 700 | 1 | |a Skyllberg, Erik W |e verfasserin |4 aut | |
| 700 | 1 | |a Durrant, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Neda A |e verfasserin |4 aut | |
| 700 | 1 | |a Madani, Yasser |e verfasserin |4 aut | |
| 700 | 1 | |a Naran, Prasheena |e verfasserin |4 aut | |
| 700 | 1 | |a Vijayakumar, Bavithra |e verfasserin |4 aut | |
| 700 | 1 | |a Tate, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Trevelyan, Gareth E |e verfasserin |4 aut | |
| 700 | 1 | |a Zaki, Irfan |e verfasserin |4 aut | |
| 700 | 1 | |a Doig, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Lynch, Geraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Warwick, Gill |e verfasserin |4 aut | |
| 700 | 1 | |a Aujayeb, Avinash |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Karl A |e verfasserin |4 aut | |
| 700 | 1 | |a Iftikhar, Hina |e verfasserin |4 aut | |
| 700 | 1 | |a Noble, Jonathan H |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Anthony Y K C |e verfasserin |4 aut | |
| 700 | 1 | |a Nugent, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Philip J |e verfasserin |4 aut | |
| 700 | 1 | |a Hastings, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Bellenberg, Harry R |e verfasserin |4 aut | |
| 700 | 1 | |a Lawrence, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Saville, Rachel L |e verfasserin |4 aut | |
| 700 | 1 | |a Johl, Nikolas T |e verfasserin |4 aut | |
| 700 | 1 | |a Grey, Adam N |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Huw C |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Thomas L |e verfasserin |4 aut | |
| 700 | 1 | |a Maddekar, Nadeem |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Shahul Leyakathali |e verfasserin |4 aut | |
| 700 | 1 | |a Muhammad, Ambreen Iqbal |e verfasserin |4 aut | |
| 700 | 1 | |a Ghani, Hakim |e verfasserin |4 aut | |
| 700 | 1 | |a Myint, Yadee Maung Maung |e verfasserin |4 aut | |
| 700 | 1 | |a Rafique, Cecillia |e verfasserin |4 aut | |
| 700 | 1 | |a Pippard, Benjamin J |e verfasserin |4 aut | |
| 700 | 1 | |a Irving, Benjamin R H |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Fawad |e verfasserin |4 aut | |
| 700 | 1 | |a Asimba, Viola H |e verfasserin |4 aut | |
| 700 | 1 | |a Azam, Aqeem |e verfasserin |4 aut | |
| 700 | 1 | |a Barton, Eleanor C |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatnagar, Malvika |e verfasserin |4 aut | |
| 700 | 1 | |a Blackburn, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Millington, Kate J |e verfasserin |4 aut | |
| 700 | 1 | |a Budhram, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Bunclark, Katherine L |e verfasserin |4 aut | |
| 700 | 1 | |a Sapkal, Toshit P |e verfasserin |4 aut | |
| 700 | 1 | |a Dixon, Giles |e verfasserin |4 aut | |
| 700 | 1 | |a Harries, Andrew J E |e verfasserin |4 aut | |
| 700 | 1 | |a Ijaz, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Karunanithi, Vijayalakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Naik, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Malik Aamaz |e verfasserin |4 aut | |
| 700 | 1 | |a Savlani, Karishma |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Vimal |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego, Beatriz Lara |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdi, Noor A |e verfasserin |4 aut | |
| 700 | 1 | |a Morgan, Caitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Neena |e verfasserin |4 aut | |
| 700 | 1 | |a Rowlands, Elen W |e verfasserin |4 aut | |
| 700 | 1 | |a Steward, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Thorley, Richard S |e verfasserin |4 aut | |
| 700 | 1 | |a Wollerton, Rebecca L |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah, Sana |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Lason, Wojciech |e verfasserin |4 aut | |
| 700 | 1 | |a Rostron, Anthony J |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Najib M |e verfasserin |4 aut | |
| 700 | 1 | |a Hallifax, Rob J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g (2022) vom: 12. Mai |w (DE-627)NLM012664782 |x 0903-1936 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:12 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.02522-2021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 12 |c 05 | ||